title: Treatment of Parkinson's disease with proglumide, a CCK antagonist.
abstract: Proglumide, a cholecystokinin antagonist, did not improve Parkinson's disease in a preliminary drug treatment trial.
authors.affiliation: Department of Neurology, School of Medicine, University of Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Piolti
authors.forename: I
authors.initials: I
authors.lastname: Appollonio
authors.forename: E
authors.initials: E
authors.lastname: Cocco
authors.forename: C
authors.initials: C
authors.lastname: Ferrarese
authors.forename: L
authors.initials: L
authors.lastname: Frattola
authors.forename: L
authors.initials: L
authors.lastname: Rovati
authors.forename: A E
authors.initials: AE
authors.lastname: Panerai
mesh_terms: D000368:Aged; D002766:Cholecystokinin / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011377:Proglumide / Q000627:therapeutic use*
chemical_list: D007980:Levodopa; D002766:Cholecystokinin; D011377:Proglumide